---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010647"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:09:39.115251+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback

## Summary
- Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.
- Jornay PM net revenue $32.6M, prescriptions up 23% YoY; full-year Jornay PM guidance raised to $140-145M.
- Pain portfolio revenue $155.4M (+7% YoY) with Belbuca $52.6M, Xtampza $52.6M, Nucynta $46.4M.
- Raised FY2025 revenue guidance to $745-760M and adjusted EBITDA to $440-455M; cash $222.2M.
- Board authorized $150M share repurchase through Dec 2026; completed $25M ASR in July.

## SEC filing metadata
- accession: 0001558370-25-010647
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/0001558370-25-010647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/coll-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010647
- JSON: https://secwatch.observer/filing/0001558370-25-010647.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.